Looking back at a non-invasive skin scan used to diagnose basal cell carcinoma
Reviews how well LC-OCT imaging works in routine care for suspected basal cell carcinoma.
Plain-language title generated from the registry record
Registry title: Real-world Evaluation of the Implementation of LC-OCT in Daily Clinical Practice
Key facts
- Where
- Maastricht, NetherlandsSee the site
Where in Netherlands
- Maastricht University Medical CenterMaastricht, NetherlandsTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Maastricht University Medical Center
- Trial code
- NCT07501780
- Record updated
- 19 October 2026
- Original description
Basal cell carcinoma (BCC) is the most common skin cancer in the Netherlands, with incidence rates continuing to rise. The current diagnostic standard combines clinical evaluation and dermoscopy, while biopsy followed by histopathological examination remains the gold standard when uncertainty about the diagnosis persists. However, biopsy is invasive, time-consuming, and costly. Line-field confocal optical coherence tomography (LC-OCT) is a non-invasive imaging technique that has emerged as a promising alternative to biopsy for BCC suspected lesions.Read full original descriptionShow less
Real-world Evaluation of the Implementation of LC-OCT in Daily Clinical Practice: a Retrospective Observational Study
Basal cell carcinoma (BCC) is the most common skin cancer in the Netherlands, with incidence rates continuing to rise. The current diagnostic standard combines clinical evaluation and dermoscopy, while biopsy followed by histopathological examination remains the gold standard when uncertainty about the diagnosis persists. However, biopsy is invasive, time-consuming, and costly. Line-field confocal optical coherence tomography (LC-OCT) is a non-invasive imaging technique that has emerged as a promising alternative to biopsy for BCC suspected lesions.
This retrospective study aims to evaluate the real-world clinical performance of LC-OCT in routine dermatological practice, where it has been integrated into the diagnostic work-up for BCC-suspect lesions.
Inclusion: Patients aged ≥18 years; LC-OCT performed as part of diagnostic evaluation between January 2025 and June 2025 at Mohs clinics in the Netherlands; Histopathological results (biopsy or excision) and/or 6-12 month clinical follow-up data available.
Exclusion: Patients <18 years of age; Cases without histopathological confirmation or available follow-up data.